Objective: Meningococcal disease (MCD) remains a medical emergency and a frequent cause of death in previously healthy individuals. We aimed to determine the frequency and cause of delays in antibiotic administration in a cohort of deaths.

Methods: A retrospective chart review was undertaken on 140 hospitalised MCD deaths within New Zealand's serogroup B epidemic (1993-2004).

Results: Death after hospital presentation occurred rapidly (median 12 h) with 70% dying within 24 h. Delays of more than 2 h in time-to-antibiotic post hospital presentation occurred in 29%. The major contributors to these delays were the failure to include MCD within the differential diagnosis and prolonged assessment times. Multivariate logistic regression analysis, undertaken by combining study deaths which had meningococcal bacterial load results (n=9) with a survivor cohort (n=126) from a previous study, confirmed bacterial load as a major predictor of death (OR 7.5 per log10 cfu/mL increase; 95% CI 2.2-25.3; p=0.001). A non-significant increased risk of death per hour of antibiotic delay was seen (OR 1.18; 95% CI 0.90-1.55; p=0.22).

Conclusions: Death from MCD occurred rapidly, with many patients not receiving antibiotics at the earliest opportunity. The introduction of recently developed rapid diagnostic markers into the identified delay-intervals could lead to a reduction in time-to-antibiotic and hopefully reduce case-fatality rates.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jinf.2006.10.050DOI Listing

Publication Analysis

Top Keywords

meningococcal disease
8
antibiotic administration
8
hospital presentation
8
presentation occurred
8
occurred rapidly
8
bacterial load
8
death
5
disease deaths
4
deaths frequency
4
frequency antibiotic
4

Similar Publications

To investigate the safety of the tetravalent meningococcal conjugate vaccine (MPCV-ACYW) in combination with the inactivated poliomyelitis (IPV) vaccine and diphtheria-tetanus-acellular pertussis (DTaP) vaccine for infants aged 3-5 months and provide real-world evidence for the immunization strategy of vaccine combination. From June to October 2023, a total of 600 3-month-old infants were selected and divided into three groups: control group, mono-vaccination group and combined vaccination group. They were simultaneously or individually vaccinated with MPCV-ACYW, IPV and DTaP vaccines at 3, 4, and 5 months of age, respectively.

View Article and Find Full Text PDF

October 2024 ACIP Meeting Update: Influenza, COVID-19, RSV and Other Vaccines.

Pediatrics

January 2025

Department of Pediatrics, University of Cincinnati College of Medicine and Division of Pediatric Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati OH.

The Advisory Committee on Immunization Practices (ACIP), a group of medical and public health experts that provides advice to the Centers for Disease Control and Prevention, normally meets 3 times per year to develop US vaccine recommendations. The ACIP met October 23-24, 2024, to discuss influenza vaccines, chikungunya vaccines, coronavirus disease (COVID-19) vaccines, RSV immunizations, meningococcal vaccines, human papillomavirus (HPV) vaccines, pneumococcal vaccines, and adult and child/adolescent immunization schedule revisions. This update summarizes the proceedings of these meetings, with an emphasis on topics that are most relevant to the pediatric population.

View Article and Find Full Text PDF

The AEP 2025 Vaccination and Immunization Schedule recommended for children, adolescents and pregnant women residing in Spain features the following novelties: Due to the increase in measles cases and outbreaks in recent years, we recommend advancing the second dose of measles, mumps and rubella (MMR) vaccine to 2 years of age. As a consequence of the above, since many autonomous communities (ACs) use the quadrivalent vaccine for the second dose of MMR and varicella vaccines, we recommend, for all ACs, advancing the second dose of varicella vaccine to 2 years of age. Due to the very significant increase in cases of pertussis since late 2023 and especially in 2024, we recommend advancing the dose of Tdap given in adolescence to 10-12 years of age.

View Article and Find Full Text PDF

Erratum: Meningococcal Surveillance Australia: Reporting period 1 April to 30 June 2024.

Commun Dis Intell (2018)

January 2025

World Health Organisation Collaborating Centre for STI and AMR, Sydney and Neisseria Reference Laboratory, Department of Microbiology, NSW Health Pathology, The Prince of Wales Hospital, Randwick, 2031, NSW Australia.

Erratum to 2024;48. (doi: 10.33321/cdi.

View Article and Find Full Text PDF

Objectives: is a significant pathogen causing invasive meningococcal disease, posing clinical and public health concerns worldwide. This study aimed to investigate the genetic characteristics of clinical isolates at Okayama University Hospital in Japan.

Methods: Between 2018 and 2023, five clinical strains were isolated, of which three were subjected to the antimicrobial susceptibility testing and whole genetic analysis using MiSeq platform (Illumina, San Diego, CA, USA).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!